Literature DB >> 32399431

Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma.

Stephen Lam Chan1, Lin-Lee Wong2,3, Kwan-Chee Allen Chan4, Chit Chow5, Joanna Hung-Man Tong5, Terry Cheuk-Fung Yip6, Grace Lai-Hung Wong6, Charing Ching-Ning Chong7, Po-Hong Liu8,9, Cheuk-Man Chu10, Vincent Wai-Sun Wong6, Ka-Fai To5, Helen L Reeves3,11, Anthony Wing-Hung Chan5.   

Abstract

BACKGROUND: The aim of current study was to (1) construct and validate a novel hepatocellular carcinoma (HCC)-specific inflammatory index; (2) compare the performances of the Integrated Liver Inflammatory Score (ILIS) to existing 4 inflammatory indices in HCC; (3) explore the association between the inflammatory indices and systemic/intratumoral inflammatory markers.
METHODS: Two cohorts from Hong Kong (HK; n = 1,315) and Newcastle (n = 574) were studied. A novel index was constructed from the HK training set (n = 627). The index was constructed from the training set by combing independent prognostic circulating parameters, followed by validating in the validation set of HK cohort (n = 688) and the Newcastle cohort. Its prognostic performance was compared to 4 inflammatory indices, namely, the neutrophil to lymphocyte ratio, platelet-to-lymphocyte ratio, prognostic nutrition index, and systemic immune-inflammation index, were compared in the HK cohort. Circulating cytokines and intratumoral gene expression were analyzed in a subset of patients with available samples and correlated with the inflammatory indices.
RESULTS: In the training set of the HK cohort, the ILIS, was generated: -0.057 × albumin (g/L) + 0.978 × log (Bilirubin, µmol/L) + 1.341 × log (alkaline phosphatase, IU/L) + 0.086 × Neutrophil (10<sup>9</sup>/L) + 0.301 × log (alpha-fetoprotein, µg/L). With cutoff of 2.60 and 3.87, the ILIS could categorize patients into 3 risk groups in the both validation cohorts. ILIS outperforms other inflammatory indices and remains an independent prognosticator for overall survival after adjustment with Barcelona Clinic Liver Cancer (hazard ratio 31.90, p < 0.001). The ILIS had the best prognostic performances as compared to other inflammatory indices. In exploratory analyses, the ILIS correlated with circulating inflammatory cytokines (e.g., IL-8) but not with any intratumoral inflammatory gene expression.
CONCLUSIONS: ILIS is an HCC-specific prognostic index built on 5 readily available blood parameters. Its versatility is validated both Eastern and Western population of HCC. The score is correlated with levels of circulating cytokines.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  Inflammation; Liver cancer; Prognosis; Tumor markers

Year:  2019        PMID: 32399431      PMCID: PMC7206612          DOI: 10.1159/000504252

Source DB:  PubMed          Journal:  Liver Cancer        ISSN: 1664-5553            Impact factor:   11.740


  39 in total

1.  Lymphocyte to monocyte ratio and neutrophil to lymphocyte ratio are superior inflammation-based predictors of recurrence in patients with hepatocellular carcinoma after hepatic resection.

Authors:  Tianbo Yang; Jiye Zhu; Lei Zhao; Kangye Mai; Jiazhou Ye; Shan Huang; Yinnong Zhao
Journal:  J Surg Oncol       Date:  2017-01-27       Impact factor: 3.454

2.  Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.

Authors:  Stephen J Bagley; Shawn Kothari; Charu Aggarwal; Joshua M Bauml; Evan W Alley; Tracey L Evans; John A Kosteva; Christine A Ciunci; Peter E Gabriel; Jeffrey C Thompson; Susan Stonehouse-Lee; Victoria E Sherry; Elizabeth Gilbert; Beth Eaby-Sandy; Faith Mutale; Gloria DiLullo; Roger B Cohen; Anil Vachani; Corey J Langer
Journal:  Lung Cancer       Date:  2017-01-25       Impact factor: 5.705

3.  The Severity of Liver Fibrosis Influences the Prognostic Value of Inflammation-Based Scores in Hepatitis B-Associated Hepatocellular Carcinoma.

Authors:  Qin Wang; Sima Blank; M Isabel Fiel; Hena Kadri; Wei Luan; Leslie Warren; Aileen Zhu; P Alexander Deaderick; Umut Sarpel; Daniel M Labow; Spiros P Hiotis
Journal:  Ann Surg Oncol       Date:  2015-07-10       Impact factor: 5.344

4.  Systematic evaluation of circulating inflammatory markers for hepatocellular carcinoma.

Authors:  Stephen L Chan; Anthony W H Chan; Allen K C Chan; Peiyong Jian; Frankie Mo; Charles M L Chan; Kevin Mok; Calvin Liu; Charing C N Chong; Anthony T C Chan; Tony Mok; Winnie Yeo
Journal:  Liver Int       Date:  2016-08-29       Impact factor: 5.828

5.  Applicability of albumin-bilirubin-based Japan integrated staging score in hepatitis B-associated hepatocellular carcinoma.

Authors:  Anthony W H Chan; Charing C N Chong; Frankie K F Mo; John Wong; Winnie Yeo; Philip J Johnson; Shuangni Yu; Paul B S Lai; Anthony T C Chan; Ka-Fai To; Stephen L Chan
Journal:  J Gastroenterol Hepatol       Date:  2016-10       Impact factor: 4.029

6.  Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer.

Authors:  Chan-Young Ock; Ah-Rong Nam; Joongyub Lee; Ju-Hee Bang; Kyung-Hun Lee; Sae-Won Han; Tae-Yong Kim; Seock-Ah Im; Tae-You Kim; Yung-Jue Bang; Do-Youn Oh
Journal:  Gastric Cancer       Date:  2016-05-05       Impact factor: 7.370

7.  Incorporating albumin-bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma.

Authors:  Anthony W H Chan; Charing C N Chong; Frankie K F Mo; John Wong; Winnie Yeo; Philip J Johnson; Shuangni Yu; Paul B S Lai; Anthony T C Chan; Ka-Fai To; Stephen L Chan
Journal:  J Gastroenterol Hepatol       Date:  2017-01       Impact factor: 4.029

8.  Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients.

Authors:  P F Ferrucci; S Gandini; A Battaglia; S Alfieri; A M Di Giacomo; D Giannarelli; G C Antonini Cappellini; F De Galitiis; P Marchetti; G Amato; A Lazzeri; L Pala; E Cocorocchio; C Martinoli
Journal:  Br J Cancer       Date:  2015-05-26       Impact factor: 7.640

9.  Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?

Authors:  Jane Margetts; Laura F Ogle; Stephen L Chan; Anthony W H Chan; K C Allen Chan; David Jamieson; Catherine E Willoughby; Derek A Mann; Caroline L Wilson; Derek M Manas; Winnie Yeo; Helen L Reeves
Journal:  Br J Cancer       Date:  2017-11-09       Impact factor: 7.640

10.  Differential Serum Cytokine Profiles in Patients with Chronic Hepatitis B, C, and Hepatocellular Carcinoma.

Authors:  Jacqueline Estevez; Vincent L Chen; Ondrej Podlaha; Biao Li; An Le; Philip Vutien; Ellen T Chang; Yael Rosenberg-Hasson; Zhaoshi Jiang; Stefan Pflanz; Dongliang Ge; Anuj Gaggar; Mindie H Nguyen
Journal:  Sci Rep       Date:  2017-09-19       Impact factor: 4.379

View more
  8 in total

1.  Prognostic models for outcome prediction in patients with advanced hepatocellular carcinoma treated by systemic therapy: a systematic review and critical appraisal.

Authors:  Li Li; Xiaomi Li; Wendong Li; Jinglong Chen; Wei Li; Xiaoyan Ding; Yongchao Zhang
Journal:  BMC Cancer       Date:  2022-07-09       Impact factor: 4.638

2.  Prognostic Significance of Preoperative Integrated Liver Inflammatory Score in Patients with Hepatocellular Carcinoma.

Authors:  Biao Wu; Yumeng Wu; Xianlin Guo; Yifei Liu; Yanping Yue; Wenjing Zhao; Jibin Liu; Xuming Wu; Aiguo Shen; Suqing Zhang
Journal:  Med Sci Monit       Date:  2022-06-21

Review 3.  Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations.

Authors:  Adam Hatzidakis; Lukas Müller; Miltiadis Krokidis; Roman Kloeckner
Journal:  Cancers (Basel)       Date:  2022-05-17       Impact factor: 6.575

4.  Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival.

Authors:  Shu-Kui Qin; Qing Li; Jian Ming Xu; Jun Liang; Ying Cheng; Ying Fan; Jun Jiang; Hao Ye; Huimin Tao; Lian Li; Limin Zheng; Zhaohui Wei; Shu Li; Kun Meng; Bin Ye; Yan Sun
Journal:  Cancer Sci       Date:  2020-09-24       Impact factor: 6.716

5.  Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade.

Authors:  Tsz Tung Kwong; Chi Hang Wong; Jing Ying Zhou; Alfred Sze Lok Cheng; Joseph Jao Yiu Sung; Anthony Wing Hung Chan; Stephen Lam Chan
Journal:  JHEP Rep       Date:  2020-12-20

6.  Combination of Tertiary Lymphoid Structure and Neutrophil-to-Lymphocyte Ratio Predicts Survival in Patients With Hepatocellular Carcinoma.

Authors:  Shaodi Wen; Yuzhong Chen; Chupeng Hu; Xiaoyue Du; Jingwei Xia; Xin Wang; Wei Zhu; Qingbo Wang; Miaolin Zhu; Yun Chen; Bo Shen
Journal:  Front Immunol       Date:  2022-01-13       Impact factor: 7.561

7.  Prognostic and Clinical Significance of Aspartate Aminotransferase-to-Lymphocyte Ratio Index in Individuals with Liver Cancer: A Meta-Analysis.

Authors:  Xiulan Peng; Yali Huang; Min Zhang; Yan Chen; Lihua Zhang; Anbing He; Renfeng Luo
Journal:  Dis Markers       Date:  2022-02-09       Impact factor: 3.434

8.  Physical activity attenuates the associations of systemic immune-inflammation index with total and cause-specific mortality among middle-aged and older populations.

Authors:  Hang Li; Xiulong Wu; Yansen Bai; Wei Wei; Guyanan Li; Ming Fu; Jiali Jie; Chenming Wang; Xin Guan; Yue Feng; Hua Meng; Mengying Li; Meian He; Xiaomin Zhang; Huan Guo
Journal:  Sci Rep       Date:  2021-06-15       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.